Modulators of Rho C activity

Details Modulators of Rho C activity Modulators of Rho C activity

2006-05-30

2006-05-30

Wilson, James O. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S266300, C514S266310, C514S266400

Reexamination Certificate

active

07053216

ABSTRACT:
Compounds of formula 1 modulate the activity of Rho C:wherein R1is H, lower alkyl, aralkyl, aryl-lower alkenyl, or —(CH2)nCH(R7)NR8R9, where n is 0–6 inclusive, R7is H, lower alkyl, aryl, or aralkyl, R8is H, lower alkyl, cyclo-alkyl, aryl, or aralkyl, and R9is R, RCO—, ROCO—, or RNHCO—, where R is lower alkyl, cycloalkyl, aryl, or aralkyl, wherein aryl and aralkyl are substituted with 0–3 substituents selected from the group consisting of lower alkyl, halo, nitro, —OH, trifluoromethyl, or lower alkoxy;R2is lower alkyl, aryl, aralkyl, or —(CHR10)m—(CO)—R11, wherein m is 0–4, R10is H or lower alkyl, and R11is lower alkyl, cycloalkyl, aryl, or aralkyl, wherein aryl and aralkyl are substituted with 0–3 substituents selected from the group consisting of lower alkyl, halo, nitro, —OH, trifluoromethyl, or lower alkoxy;R3, R4, R5, and R6, are each independently H, lower alkyl, halo, nitro, OH, lower alkoxy, NH2, lower alkylamino, di(lower alkylamino), trifluoromethyl, or SH;or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 2651632 (1953-09-01), Baker et al.
patent: 3047462 (1962-07-01), George et al.
patent: 3060090 (1962-10-01), Becker
patent: 3135659 (1964-06-01), Bola et al.
patent: 3304304 (1967-02-01), Henricus et al.
patent: 3317388 (1967-05-01), Bola et al.
patent: 3515787 (1970-06-01), Brener et al.
patent: 3558610 (1971-01-01), Brener et al.
patent: 3651230 (1972-03-01), Yamamoto et al.
patent: 3696102 (1972-10-01), Cronin
patent: 3714354 (1973-01-01), Stam
patent: 3755581 (1973-08-01), Janiak
patent: 3907995 (1975-09-01), Yabutani et al.
patent: 3991193 (1976-11-01), Taylor et al.
patent: 4054658 (1977-10-01), Buehler et al.
patent: 4668682 (1987-05-01), Sekiya et al.
patent: 4714702 (1987-12-01), Inoue et al.
patent: 5283247 (1994-02-01), Dwivedi et al.
patent: 5470878 (1995-11-01), Michnick et al.
patent: 5948775 (1999-09-01), Koko et al.
patent: 6136812 (2000-10-01), Chenard et al.
patent: 6303615 (2001-10-01), Elliott et al.
patent: 6331555 (2001-12-01), Hirth et al.
patent: 6545004 (2003-04-01), Finer et al.
patent: 10-259176 (1998-09-01), None
patent: WO 96/28430 (1996-09-01), None
patent: WO 97/43276 (1997-11-01), None
patent: WO 99/24563 (1999-05-01), None
patent: WO 01/030768 (2001-05-01), None
Debnath, K. A. et. al., “Structure-Based Identification of Small Molecule Antiviral Compounds . . . ”, J. Med. Chem., 1999, vol. 42, No. 17, pp. 3203-3209.
Badr, M.Z.A. et.al., “Electronic impact-promoted fragmentation of some substituted 4-quinazolones.” Chem. Abs., 1997, vol. 124, Abstract #175,225.
Parasharya, P.M. et. al., “4-(3-H)-Quinazolones: . . . ” Chem. Abs., 1997, vol. 121, Abstract #134,062.
Aktories, “Rho proteins: targets for bacterial toxins,”Trends Microbiol. 5(7):282-288, 1997.
Boman et al., “Arf proteins: the membrane traffic police?”Trends Biochem. Sci. 20(4):147-150, 1995.
Box, “ras Oncogenes in human cancer: a review,”Cancer Res. 49(17):4682-4689, 1989.
Cerione et al., “The Dbl family of oncogenes,”Curr. Ipin. Cell Biol. 8(2):216-222, 1996.
Chavrier et al., “The role of ARF and Rab GTPases in membrane transport,”Curr. Opin. Cell Biol. 11(4):466-475, 1999.
Clark et al., “Genomic analysis of metastasis reveals an essential role for RhoC,”Nature406:532-535, 2000.
End, “Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway,”Invest New Drugs17(3):241-258, 1999.
Fritz et al., “Rho GTPases are over-expressed in human tumors,”Int. J. Cancer81(5):682-687, 1999.
Ganguly et al., “Detection and structural characterization of Ras oncoprotein-inhibitors complexes by electrospray mass spectrometry,”Bioorg. Med. Chem. 5(5):817-820, 1997.
Ganguly et al., “Interaction of a novel GDP exchange inhibitor with the Ras protein,”Biochemistry37(45):15631-15637, 1998.
Hall, “Ras-related proteins,”Curr.Opin. Cell Biol. 5(2):265-268, 1993.
Hall, “Rho GTPases and the actin cytoskeleton,”Science279:509-514, 1998.
Helliwell et al., “The Rho1 effector Pkc1, but not Bnil, mediates signalling from Tor2 to the actin cytoskeleton,”Curr. Biol. 8(22):1211-1214, 1998.
Ihara et al., “Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue,”J. Biol. Chem. 273(16):9656-9666, 1998.
Kaibuchi et al., “Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells,”Ann. Rev. Biochem. 68:459-486, 1999.
Kohl, “Farnesyltransferase inhibitors preclinical development,”Ann. NY Acad. Sci. 886:91-102, 1999.
Kumar et al., “SCH 51344, an inhibitor of Ras/Rac-mediated cell morphology pathway,”Ann. NY Acad. Sci886:122-131, 1999.
Longenecker et al., “How RhoGDI binds Rho,”Acta Crystallogr. D. Biol. Crystallogr 55(Pt 9):1503-1515, 1999.
Mackay et al., “Rho GTPases,”J. Biol. Chem. 273:20685-20688, 1998.
Maesaki et al., “The structural basis of Rho effector recognition revealed by the crystal structure of human RhoA complexed with the effector domain of PKN/PRK1,”Mol. Cell4(5):793-803, 1999.
Maesaki et al., “Biochemical and crystallographic characterization of a Rho effector domain of the protein serine/threonine kinase N in a complex with RhoA,”J. Struct. Biol. 126:166-170, 1999.
Martinez et al., “Rab proteins,”Biochem Biophys Acta1404(1-2):101-112, 1998.
Moore, “Ran and nuclear transport,”J. Biol. Chem. 273(36):22857-22860, 1998.
Nomanbhoy et al., “Kinetics of cdc42 membrane extraction by Rho-GDI monitored by real-time fluorescence resonance energy transfer,”Biochemistry38(6):1744-1750, 1999.
Read et al., “Human RhoA/RhoGDI complex expressed in yeast: GTP exchange is sufficient for translocation of RhoA to liposomes,”Protein Sci. 9(2):376-386, 2000.
Rittinger et al., “Crystal structure of a small G protein in complex with the GTPase-activating protein rhoGAP,”Nature388:693-697, 1997.
Rush et al., “The small nuclear GTPase ran: how much does it run?”Bioessays18(2):103-112, 1996.
Schmidt et al., “Bacterial cytotoxins target Rho GTPases,”Naturwissenschaften85(6):253-261, 1998.
Schimmöller et al., “Rab GTPases, directors of vesicle docking,”J. Biol. Chem. 273(35):22161-22214, 1998.
Shimizu et al., “An open conformation of switch I revealed by the crystal structure of a Mg2+-free form of RHOA complexed with GDP,”J. Biol. Chem. 275(24):18311-18317, 2000.
Suwa et al., “Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas,”Br. J. Cancer77(1): 147-152, 1998.
Tanaka et al., “Control of reorganization of the actin cytoskeleton by Rho family small GTP-binding proteins in yeast,”Curr. Opin. Cell Biol. 10(1):112-116, 1998.
Taveras et al., “Ras oncoprotein inhibitors: the discovery of potent, Ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex,”Bioorg. Med. Chem. 5(1):125-133, 1997.
Vojtek et al., “Increasing complexity of the Ras signaling pathway,”J. Biol. Chem. 273(32):19925-19928, 1998.
Watanabe et al., “Cooperation between mDial and ROCK in Rho-induced actin reorganization,”Nat. Cell Biol. 1(3):136-143, 1999.
Whitehead et al., “Dbl family proteins,”Biochem. Biophys. Acta1332(1):F1-23, 1997.
Yoshioka et al., “Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells,”Cancer Res. 59(8):2004-2010, 1999.
Gershbein et al., “Action of drugs and chemical agents on rat liver regeneration,” Chem. Abst. 103(21): Abstract #103:172042b, 1985.

Affiliated with

Also associated with

Rating

Modulators of Rho C activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulators of Rho C activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of Rho C activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3616553